## Pifithrin-α, p-Nitro, Cyclic

MedChemExpress

Cat. No.:	HY-123076
CAS No.:	60477-38-5
Molecular Formula:	C <sub>15</sub> H <sub>13</sub> N <sub>3</sub> O <sub>2</sub> S
Molecular Weight:	299.35
Target:	MDM-2/p53
Pathway:	Apoptosis
Storage:	-20°C, stored under nitrogen
	* In solvent : -80°C, 2 years; -20°C, 1 year (stored under nitrogen)

## SOLVENT & SOLUBILITY

In Vitro

DMF : 12.5 mg/mL (41.76 mM; Need ultrasonic)
DMSO : 5 mg/mL (16.70 mM; Need ultrasonic)

	Mass Solvent Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.3406 mL	16.7029 mL	33.4057 mL
	5 mM	0.6681 mL	3.3406 mL	6.6811 mL
	10 mM	0.3341 mL	1.6703 mL	3.3406 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY			
Description	Pifithrin- $\alpha$ , p-Nitro, Cyclic (PFN- $\alpha$ ) is cell-permeable and active-form p53 inhibitor. Pifithrin- $\alpha$ , p-Nitro, Cyclic is one order magnitude more active than Pifithrin- $\alpha$ in protecting cortical neurons exposed to Etoposide (ED <sub>50</sub> =30 nM). Pifithrin- $\alpha$ , p-Nitro, Cyclic behaves as a p53 posttranscriptional activity inhibitor. Pifithrin- $\alpha$ , p-Nitro, Cyclic do not prevent p53 phosphorylation on the S15 residue <sup>[1][2]</sup> .		
In Vitro	Pifithrin-α, p-Nitro, Cyclic (PFN-α) efficiently blocks p53-triggered cell death and p21/WAF1 expression in cortical neurons exposed to etoposide at concentrations one order magnitude lower than that in PFT-α <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	Intraocular injection of pifithrin-α slightly increases survival of retinal ganglion cell (RGC) at the concentration of 6 μM but not at 0.06 μM. Pifithrin-α, p-Nitro, Cyclic (PFN-α) is not effective in vivo, even at 6 μM <sup>[1]</sup> . Pifithrin-α, p-Nitro, Cyclic shows the half-life (t <sub>1/2</sub> ) of 6 hours (when incubated in biological conditions) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

0 -- N, O-

## CUSTOMER VALIDATION

- Antioxidants (Basel). 2023 Aug 22, 12(9), 1657.
- Biomolecules. 2023, 13(2), 392.
- FASEB J. 2022 Dec;36(12):e22672.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. Pietrancosta N, et al. Imino-tetrahydro-benzothiazole derivatives as p53 inhibitors: discovery of a highly potent in vivo inhibitor and its action mechanism. J Med Chem. 2006 Jun 15;49(12):3645-52.

[2]. Dinca EB, et al. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res. 2008 Dec 15;68(24):10034-9.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA